A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis

Trial Profile

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs NEOD 001 (Primary)
  • Indications Amyloidosis
  • Focus Registrational; Therapeutic Use
  • Acronyms VITAL
  • Sponsors Onclave Therapeutics; Prothena
  • Most Recent Events

    • 16 Nov 2017 According to a Prothena media release, highlights from the study will be discussed during R&D Day.
    • 14 Aug 2017 Planned End Date changed from 1 Aug 2018 to 1 Feb 2019.
    • 14 Aug 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top